Document Detail


Population pharmacokinetics of halofantrine in healthy volunteers and patients with symptomatic falciparum malaria.
MedLine Citation:
PMID:  23058047     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIMS: To investigate the population pharmacokinetics of the antimalarial halofantrine (HF) in healthy volunteers and patients with symptomatic falciparum malaria.
METHODS: Healthy volunteer data were obtained from six volunteers who received three different doses of HF (250, 500 and 1000 mg) after an overnight fast with a washout period of at least 6 weeks between doses. Patient data (n = 188) were obtained from randomised controlled trials conducted on the Thai-Burmese border in the early 1990s. They were either assigned to receive a total HF dose of 24 mg/kg (8 mg/kg every 6 h for 24 h) or 72 mg/kg (8 mg/kg every 6 to 10 h for 3 days). The population pharmacokinetics of HF were evaluated using non-linear mixed effects modelling with a two-compartment model with first-order absorption.
KEY FINDINGS: The population estimates of apparent clearance (CL), volume of compartment one (V1), distributional clearance (CLD) and volume of compartment two (V2) of HF in healthy volunteers were 2453 l/day (102 l/h), 2386 l, 716 l/day (29.8 l/h) and 2641 l, respectively. The population estimates of the PK parameters in patients were 429 l/day (17.9 l/h), 729 l, 178 l/day (7.42 l/h) and 1351 l, respectively. All PK parameters were significantly related to body weight and some were related to sex, sampling method, pre-treatment parasite density and whether patients vomited or not. When the two datasets were analysed jointly using a maximum likelihood method, the population estimates in patients were 196 l/day (8.17 l/h), 161 l, 65 l/day (2.71 l/h) and 89 l, respectively, and the parameters were significantly related to body weight and sex. Bayesian analysis of the patient data, with a diffuse prior based on the healthy volunteer data analysis results, yielded the population estimates 354 l/day (14.8 l/h), 728 l, 162 l/day (6.75 l/h) and 1939 l, respectively.
CONCLUSIONS: The pharmacokinetic properties of HF in patients with malaria are affected by several demographic variables as well as other relevant covariates. Apparent differences between the healthy volunteer and the patient data analysis results are not entirely due to differences in bioavailability. For the patient data analysis, the Bayesian method was preferred, as the fitting procedure was more stable, allowing random effects to be estimated for all four dispositional parameters.
Authors:
Kerenaftali Klein; Leon Aarons; Feiko O Ter Kuile; Francois Nosten; Nick J White; Michael D Edstein; Paktiya Teja-Isavadharm
Related Documents :
6186457 - Visual evoked potential changes induced by methylphenidate in hyperactive children: dos...
1594647 - Evaluation of the discriminative stimulus and reinforcing effects of sertraline in rhes...
409837 - Ketamine self-administration by the rhesus monkey.
2276597 - Pharmacologic and toxicologic effects of di(beta-phenylisopropyl)amine (dpia) in rats a...
1707337 - Evolution of neuropathy and myopathy during intensive vincristine/corticosteroid chemot...
17963857 - Noncontraceptive benefits of two combined oral contraceptives with antiandrogenic prope...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2012-07-09
Journal Detail:
Title:  The Journal of pharmacy and pharmacology     Volume:  64     ISSN:  2042-7158     ISO Abbreviation:  J. Pharm. Pharmacol.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-10-12     Completed Date:  2013-03-08     Revised Date:  2014-08-12    
Medline Journal Info:
Nlm Unique ID:  0376363     Medline TA:  J Pharm Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  1603-13     Citation Subset:  IM    
Copyright Information:
© 2012 The Authors. JPP © 2012 Royal Pharmaceutical Society.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Antimalarials / administration & dosage,  pharmacokinetics*,  therapeutic use
Bayes Theorem
Biological Availability
Body Weight
Case-Control Studies
Child
Child, Preschool
Dose-Response Relationship, Drug
Female
Humans
Infant
Likelihood Functions
Malaria, Falciparum / drug therapy*
Male
Middle Aged
Models, Biological*
Myanmar
Nonlinear Dynamics
Phenanthrenes / administration & dosage,  pharmacokinetics*,  therapeutic use
Thailand
Tissue Distribution
Young Adult
Grant Support
ID/Acronym/Agency:
089275//Wellcome Trust; 093956//Wellcome Trust
Chemical
Reg. No./Substance:
0/Antimalarials; 0/Phenanthrenes; Q2OS4303HZ/halofantrine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of microneedle treatment on the skin permeation of a nanoencapsulated dye.
Next Document:  Progesterone pharmacokinetics in the mouse: implications for potential stroke therapy.